Processa pharmaceuticals to present at h.c. wainwright 22nd annual global investment conference on september 12-14, 2022

Hanover, md, sept. 07, 2022 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced that dr. dr. david young, chief executive officer, will present at the h.c. wainwright 22nd annual global investment conference on wednesday, september 14, 2022.
PCSA Ratings Summary
PCSA Quant Ranking